ImmunityBio disclosed that its net product revenue for the quarter ended March 31 2026 reached $44.2 million, a 168% year‑over‑year increase from the $16.5 million reported in Q1 2025. The jump reflects a 15% sequential rise over Q4 2025’s $38.3 million, underscoring the continued commercial momentum of its flagship product, ANKTIVA.
The growth is driven by expanding ANKTIVA unit volumes, fueled by growing physician adoption and the inclusion of the drug in the National Comprehensive Cancer Network (NCCN) guidelines for BCG‑unresponsive non‑muscle invasive bladder cancer. The company’s CEO, Richard Adcock, noted, “ANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution. Following strong growth in 2025, we are focused on scaling in the U.S. and expanding across an increasing number of global markets.”
Despite the revenue surge, ImmunityBio remains unprofitable, reporting negative net and operating margins for the twelve months ended March 31 2026. Cash, cash equivalents, and marketable securities stood at $381 million, providing a solid liquidity base to support ongoing operations and future growth initiatives. The company’s balance sheet strength has reduced prior “going concern” concerns, but profitability remains a key focus for management.
ImmunityBio’s commercial success is complemented by regulatory and pipeline developments. The drug has received approvals or authorizations in five jurisdictions, covering roughly 34 countries, and a supplemental Biologics License Application (BLA) is on track for 2026. The pivotal QUILT‑2.005 trial for BCG‑naïve CIS is fully enrolled, and the independent data monitoring committee has confirmed adequate statistical power. These milestones position ANKTIVA for expansion into additional indications, including lung cancer.
The market reaction to the earnings was muted, with investors weighing the strong revenue growth against ongoing profitability challenges and regulatory scrutiny. The company has faced an FDA warning letter over promotional materials and a securities fraud class action alleging misrepresentations about ANKTIVA’s capabilities. Competition from J&J’s Inlexzo remains a headwind, but ImmunityBio’s expanding market access and guideline inclusion provide a competitive edge in the NMIBC segment.
The earnings release signals that ImmunityBio is on a trajectory to scale its commercial operations while navigating the typical challenges of a growth‑stage biopharmaceutical company. The company’s liquidity position and pipeline progress support a cautiously optimistic outlook, though profitability and regulatory compliance will continue to be critical factors for investors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.